Business Context and Reporting Period
This Form 8-K is a current report filed by Flex Pharma, Inc. (not Decoy Therapeutics Inc.) on September 25, 2017. The registrant is a Delaware corporation headquartered in Boston, MA, and has elected to be treated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose the availability of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is procedural, intended to satisfy Regulation FD disclosure obligations regarding investor communications.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure: The Company is furnishing a copy of its "Corporate Presentation" (Exhibit 99.1) used for investor meetings, current as of September 25, 2017.
- Disclaimer: The Company explicitly disclaims any obligation to correct or update the information contained in the presentation in the future.
- Legal Status: The information in this Form 8-K and Exhibit 99.1 is deemed "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the correct registrant name is Flex Pharma, Inc., as the input metadata incorrectly referenced Decoy Therapeutics Inc.
- Review Exhibit 99.1 (the Corporate Presentation) for actual business updates, as the 8-K text itself contains no operational data.
- Note that the presentation is not subject to future updates or corrections by the Company.
- Confirm the company's status as an emerging growth company for applicable reporting exemptions.